a variable frequency ranging from one per month to hundreds per day. Incomplete penetrance is usually observed in PRRT2 variant carriers. 6, 7 The potential mechanisms of PRRT2 variants in PRRT2-related disorders remain largely unclear. PRRT2 consists of four exons and encodes a 340-amino-acid protein with two predicted transmembrane (TM) domains in the C-terminal and one proline-rich domain in the N-terminal. Enriched in cerebral cortex, cerebellum, substantia nigra, and hippocampus, PRRT2 protein was found to involve in synaptic transmission by modulating soluble N-ethylmaleimide sensitive factor attachment protein receptor (SNARE) complex. 8 To date, more than 90 variants in PRRT2 have been included in human gene mutation database (HGMD) and most of them are nonsense or frameshift variants, causing the truncation of the protein. Among them, c.649dupC (p.R217Pfs*8) is the most frequent variant, accounting for 78.5% of mutation carriers. 9 Truncated variants leading to conspicuous reduced protein level have been reported in various in vitro studies. 1, 3, 8, 10 Besides the truncated variants, about 29 missense variants of PRRT2 are documented in PRRT2-related disorders.
However, only three of them has been functionally studied. [11] [12] [13] Therefore, the clinical significance of these alleles of PRRT2 in paroxysmal disorders is difficult to evaluate. It is of great value to perform the functional studies to address the pathogenicity of PRRT2 missense variants.
In this study, we summarized the reported missense variants in PRRT2 and performed functional experiments to investigate the alternation of subcellular location and protein expression of PRRT2 missense variants. We further assigned the pathogenicity of the missense variants according to the guidelines of American College of Medical Genetics and Genomics (ACMG). 14 
| MATERIAL S AND ME THODS

| Missense variants in PRRT2
To identify all the reported missense variants within PRRT2, we searched the HGMD (http://www.hgmd.org) that provided the most up-to-date version of PRRT2 mutation and the PubMed (https ://www. After that, the pathogenicity of PRRT2 missense variants was preliminarily evaluated according to the ACMG guidelines. 
| Plasmid constructs
| Western blot analysis
To get the protein lysate, cells were rinsed with phosphate buffer saline (PBS) and harvested in lysis buffer. After centrifuging, the supernatants were collected. Western blot was performed as previously described. 15 The GFP (1:5000) and β-actin (1:5000; Sigma-Aldrich)
antibodies were used. The blots were semiquantified by gel densitometry using the Photoshop. 
| Live cell imaging
| Statistical analyses
All the experiments were repeated at least three times independently. For the Western blot, proteins were normalized to β-actin.
Differences in the mean values between wild-type or mutant PRRT2
were analyzed by one-way ANOVA using GraphPad Prism software.
P value <0.05 was considered statistically significant. The decreased or abnormally localized mutant protein was considered functionally impaired.
TA B L E 1
c
Compound heterozygous missense variant in PRRT2 had been observed.
d
Homozygous missense variant in PRRT2 had been observed.
| RE SULTS
| Overview of the missense variants in PRRT2
After a systematic review of PRRT2-related disorders, we found a total of 29 missense variants in the literature (Table 1) . Of which, 26
were heterozygous, two (p.P279L and p.R311W) were homozygous, and one (p.G305R) was described in both homozygous and heterozygous condition. 16 The predominant phenotype of these missense variants was PKD, while BFIS and ICCA were also documented.
Two variants (p.P138A and p.D147H) had a minor allele frequency (MAF) ≥0.05 in a population database 17 and were predicted to be benign by functional software (Table 1) . Another variant (p.P216L) was found to possess 5.2% of 115 controls in an Australian study, 18 although it was predicted to be deleterious (Table 1) . Of note, these three variants were not co-segregated with the disease in the family pedigrees reported previously. 17 In addition, eight variants (p.R266W, p.S275F, p.A291V, p.G305R, p.A306T, p.S317N, p.G324E, and p.I327M) were reported to co-segregate with PKD or BFIS in multiple affected family members. [18] [19] [20] [21] [22] [23] [24] They were predicted to be deleterious by SIFT, Polyphen-2, and MutationTaster. All the eight variants but one (p.G305R) were absent in population database and our control. However, they were classified as uncertain significance variants for lack of sufficient evidence. Other 18 variants were also classified as uncertain significance variants combining the population MAF and prediction data.
| Missense variants decreased the protein level
For these variants with uncertain significance, functional experiments were required. To determine the consequence of amino acid change in PRRT2, the expression level of mutant PRRT2 was evaluated in mammalian cells. HEK293T cells were transiently transfected with N-terminal EGFP tagged wild-type or mutant PRRT2. The protein expression levels were examined by Western blot. (Figure 1 ).
The remaining 17 variants, including the benign ones, had undifferentiated expression of PRRT2 protein as wild-type (Figure 1 ).
| Missense variants affected plasma membrane localization
To further characterized the subcellular distribution of mutant PRRT2 
| Classification of the missense variants in PRRT2
Decreased protein expression or alternation of subcellular localization was considered functionally impaired. We assigned the pathogenicity of the reported missense variants of PRRT2 with functional data. As a result ( A graphical representation of amino acid change in PRRT2 was shown in Figure 3 . We found that misssense variants were clustered in exon 2 and exon 3 of PRRT2. The likely pathogenic variants marked in red were concentrated in the C-terminal of PRRT2.
| D ISCUSS I ON
PRRT2 variants are associated with various paroxysmal disorders, implying a common pathway may be involved in these disorders. Thus, it is specifically necessary to elucidate the potential mechanisms of Previous studies revealed that PRRT2 variants modified the phenotype of PKD and caused earlier age at onset, longer duration, and higher frequency of complicated PKD attacks. 7, 25 Although the potential mechanism of PRRT2 variants in PKD was largely unknown, loss-of-function leading to haploinsufficiency was believed to play a crucial role in the pathogenesis. Recently, several studies uncovered the pathophysiological mechanism of PRRT2. 8, 11, 26, 27 It was demonstrated that PRRT2 was a transmembrane protein localizing primarily to the presynaptic terminals. PRRT2 involved in synaptic vesicle fusion and the release of neurotransmitters through interacting with the synaptic proteins SNAP25 and synaptotagmin 1/2. 8, 11 Moreover, electrophysiological study showed that PRRT2 controlled the excitability of excitatory neurons by interacting with Nav1.2/Nav1.6 channels. It is widely known that the membrane localization of PRRT2 is crucial for its physiological function. We found 51.7% (15/29) brane. 29 In our study, only the C-terminal amino acid change could result in mislocalization. Possibly, membrane orientation of PRRT2 is imposed by the C-terminal, especially the TM domain.
In conclusion, a total of PRRT2 missense variants reported is firstly assessed by the ACMG guidelines. It will be of great value for its instructive and meaningful role in clinical molecular diagnosis.
Missense variants could decrease the protein level and/or impair plasma membrane localization. C-terminal of PRRT2 is crucial for its physiological function. Functional study is vital for the classification and potential mechanisms associated with PRRT2 should be further explored.
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